The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Statins & the Risk of RA

Statins & the Risk of RA

November 1, 2016 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Statins have anti-inflammatory/immunomodulatory effects that may be useful in preventing rheumatoid arthritis (RA), but previous observational studies about the risk of RA with statin use yielded conflicting results.

You Might Also Like
  • Statins May Protect Against RA
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Statin Use Tied to Lower Risk of Inflammatory Bowel Disease

Background: Two population-based studies showed a reduced risk of RA with statin use, while a case–control study showed an increased risk. Two cohort studies investigating overall unintended effects of statins revealed no change in the risk of RA, among a number of other outcomes, with statin use. The discrepancies may have resulted from small numbers of exposed cases, improper case validation or study designs comparing effects in statin users vs. nonusers or adherers vs. non-adherers, which, in the case of the pleiotropic benefits of statins, have been shown to pose challenges concerning bias eradication. [See the full article for references and sources.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Goal: Therefore, these researchers undertook a nested case–control analysis in a large population-based cohort of new statin users to define the relationship between the intensity of statin treatment and the risk of RA. They hypothesized that the immunomodulatory effect would be more pronounced, and the risk of RA would be lower, in high-intensity statin users compared with low-intensity users.

Methods: Using data from the UK Clinical Practice Research Datalink, they performed a nested case–control analysis in a population-based cohort of patients who began receiving statins between 1997 and 2009 and were followed up until a first diagnosis of RA, death, end of registration with the physician’s practice, or end of January 2011. For each case of RA, 10 age-, sex- and calendar year–matched controls were randomly selected from risk sets. They estimated the hazard ratio (HR) of incident RA in the highest quintile of duration-weighted average statin intensity compared with the lowest, using conditional logistic regression. Models were adjusted for smoking status, total cholesterol level, obesity, history of cardiovascular disease, coexistent autoimmune disease, hypothyroidism, and persistence with treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: The cohort included 528,654 new users of statins, with 1,357 new cases of RA occurring during a mean follow-up of 3.3 years, for an incidence rate of 7.9 per 10,000 person-years. Cases were more likely to be smokers, to have other autoimmune diseases and to have had lower total cholesterol levels at baseline. The incidence of RA was lower in the highest statin intensity quintile (adjusted HR 0.77 [95% confidence interval 0.63–0.95]) compared with the lowest quintile.

Conclusion: In this large population-based study, high-intensity statin treatment was associated with a 23% reduced risk of RA when compared with low-intensity statin treatment. The highest quintile of duration-weighted average statin intensity corresponded to daily treatment with atorvastatin 20–80 mg, rosuvastatin 5–40 mg, or simvastatin 80 mg. The association appeared most pronounced six months after initiation of statin treatment, continued up to three years, and gradually abated after longer-term treatment, although the confidence intervals were very wide. This is the largest study on the association of statins with RA risk to date, and the first to assess the effect of relative statin strength.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Rheumatoid Arthritis (RA), risk, Statin

You Might Also Like:
  • Statins May Protect Against RA
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Statin Use Tied to Lower Risk of Inflammatory Bowel Disease
  • Myositis AutoantibodiesTriggered by Statins

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)